4T1 Mammary Carcinoma Colonization of Metastatic Niches Is Accelerated by Obesity.
4T1 cells
breast cancer
high fat diet
immune-cells infiltration
obesity
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
04
2019
accepted:
11
07
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
17
10
2019
Statut:
epublish
Résumé
Breast cancer (BC) remains the leading cause of cancer-related deaths among women, and the chances to develop it are duplicated by obesity. Still, the impact of obesity during BC progression remains less understood. We investigated the role of obesity in tumor progression using the murine model of 4T1 mammary carcinoma in BALB/c female mice, previously high-fat-diet (HFD) fed. HFD induced obesity, metabolic impairment, and high serum and fat leptin levels. After injection of 4T1-cells, HFD-mice accelerated tumor progression and metastasis. 4T1-cells found within HFD-mice metastatic niches presented higher clonogenic potential. 4T1-cells treated
Identifiants
pubmed: 31616626
doi: 10.3389/fonc.2019.00685
pmc: PMC6764084
doi:
Types de publication
Journal Article
Langues
eng
Pagination
685Informations de copyright
Copyright © 2019 Evangelista, Salvador, Soares, Barros, Xavier, Abdo, Gualberto, Macedo, Clavijo-Salomon and Gameiro.
Références
World J Surg Oncol. 2011 May 03;9:46
pubmed: 21539750
Breast Cancer Res. 2000;2(5):331-4
pubmed: 11250725
Shock. 2016 Apr;45(4):349-58
pubmed: 26513706
Breast Cancer Res. 2011 Aug 11;13(4):R78
pubmed: 21834963
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Anticancer Res. 2009 Jul;29(7):2445-51
pubmed: 19596912
Hepatology. 2013 Jul;58(1):337-50
pubmed: 23460364
Stem Cells. 2014 Oct;32(10):2702-13
pubmed: 24989835
Immunity. 2013 Mar 21;38(3):541-54
pubmed: 23477736
J Immunol. 2000 Mar 15;164(6):2881-9
pubmed: 10706673
PLoS One. 2013 Jul 18;8(7):e68171
pubmed: 23935856
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Clin Cancer Res. 2010 Aug 15;16(16):4105-12
pubmed: 20682706
J Immunol. 2000 Feb 1;164(3):1175-84
pubmed: 10640728
Cell Cycle. 2007 Mar 1;6(5):514-7
pubmed: 17329977
J Clin Oncol. 2005 Mar 1;23(7):1370-8
pubmed: 15684320
Nat Commun. 2018 Feb 16;9(1):708
pubmed: 29453396
Blood. 1995 Oct 15;86(8):2930-7
pubmed: 7579385
Blood. 2009 May 7;113(19):4534-40
pubmed: 19224760
Blood. 2004 May 1;103(9):3349-54
pubmed: 14701687
Cancer Res. 2008 May 15;68(10):3835-43
pubmed: 18483268
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Nat Rev Endocrinol. 2011 Nov 15;8(5):263-75
pubmed: 22083089
PLoS Med. 2005 Sep;2(9):e284
pubmed: 16124834
Tumour Biol. 2014 Aug;35(8):7765-73
pubmed: 24810923
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Science. 1999 Jan 8;283(5399):212-4
pubmed: 9880251
J Immunol. 2009 Jan 1;182(1):148-53
pubmed: 19109145
Mediators Inflamm. 2010;2010:802078
pubmed: 20671929
Int J Oncol. 2002 Dec;21(6):1285-92
pubmed: 12429979
FASEB J. 2012 Dec;26(12):4855-63
pubmed: 22898923
J Clin Invest. 2011 Dec;121(12):4746-57
pubmed: 22056381
Pharmacol Ther. 2013 May;138(2):197-210
pubmed: 23353703
J Immunol. 2008 Sep 1;181(5):3291-300
pubmed: 18714001
Mol Metab. 2014 Jul 10;3(6):664-75
pubmed: 25161889
Clin Chem. 2018 Jan;64(1):154-162
pubmed: 29038151
J Biol Chem. 2006 Sep 8;281(36):26320-8
pubmed: 16825198
Clin Cancer Res. 2000 May;6(5):1755-66
pubmed: 10815894